Lentiviral Vectors; a Research Tool Used To Introduce a Gene Product Into In Vitro Systems
Lentiviral Vectors in gene treatment is a technique by which
genetically engineered viruses can be introduced, modified, or even deleted
from living organisms with the help of lentivirus. These viruses are then
injected into various target organs where they multiply and reproduce. Usually,
these viruses are produced by e-fertilization of healthy tissues with DNA that
has been taken from other sources. However, for this technology to work, the
natural genetic material, i.e., the DNA of the recipient organism, must be in
perfect order.
Lentivirus are a family of viruses that are responsible for
chronic and deadly diseases in the human and other mammalian species. The best
known lentivirus is human immunodeficiency virus (HIV), which causes AIDS. Lentiviral
vectors are derived from HIV and hence, these vectors are highly
efficient for in vivo gene delivery for gene therapies. Moreover, lentiviral
vectors are used in both gene therapy and research applications. These vectors
can also be used to treat variety of rare genetic disorders such as
Metachromatic Leukodystrophy, X-linked severe combined immunodeficiency,
X-linked Adrenoleukodystrophy, and β-thalassemia.
Thus, with increase in research and development for gene
therapies, the demand for lentiviral vectors is also increasing. For example,
in 2019, Avrobio Inc. (the U.S. based biotechnology company) started a phase I
and phase II trial for gene therapy, including lentiviral vector, for patients
with type 1 Gaucher disease; a rare, inherited metabolic disorder. Moreover, in
May 2020, Avrobio Inc. revealed how lentiviral gene therapy may potentially
correct Pompe disease manifestations in the muscle and central nervous system.
The reason why lentiviral vector therapy is more popular
than any other form of retrovirus therapy; the process is faster, more
effective, and less costly. Lentivirus is primarily a research tool used to
introduce a gene product into in vitro systems or animal models. Furthermore,
third-gen lentiviral vectors have recently been used in multiple clinical
trials to introduce genes into hematopoietic stem cells to correct primary
hemoglobinopathies and immunodeficiencies.
Comments
Post a Comment